Bad cholesterol slashed 62% by single dose of gene-editing drug in small trial

A small early-stage trial found that a single dose of a gene-editing drug reduced levels of LDL "bad" cholesterol by an average of 62% in participants, with effects lasting for months. The treatment targets the PCSK9 gene and could offer a long-term alternative to daily statin medications.